Application

WAINUA

AstraZeneca AB

Trademark/Service Mark Application, Principal Register

PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

Serial Number: 98054331
Filing Date: 06/22/2023

The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 98054331
MARK INFORMATION
*MARK WAINUA
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
LITERAL ELEMENT WAINUA
MARK STATEMENT The mark consists of standard characters, without claim to any particular font style, size, or color.
REGISTER Principal
APPLICANT INFORMATION
*OWNER OF MARK AstraZeneca AB
*MAILING ADDRESS Astraallén
*CITY Södertälje
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY Sweden
*ZIP/POSTAL CODE
(Required for U.S. and certain international addresses)
SE-15185
*EMAIL ADDRESS XXXX
LEGAL ENTITY INFORMATION
TYPE corporation
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION Sweden
GOODS AND/OR SERVICES AND BASIS INFORMATION
INTERNATIONAL CLASS 005 
*IDENTIFICATION Pharmaceutical preparations and substances for the treatment of amyloidosis
FILING BASIS SECTION 1(b)
FILING BASIS SECTION 44(d)
       FOREIGN APPLICATION NUMBER 018888666
       FOREIGN APPLICATION
       COUNTRY/REGION/JURISDICTION/U.S. TERRITORY
European Union Trademark - EUTM
       FOREIGN FILING DATE 06/15/2023
       INTENT TO
       PERFECT 44(d)
At this time, the applicant intends to rely on Section 44(e) as a basis for registration. If ultimately the applicant does not rely on Section 44(e) as a basis for registration, a valid claim of priority may be retained.
ATTORNEY INFORMATION
NAME Cara M. Kearney
ATTORNEY DOCKET NUMBER 104563/US
ATTORNEY BAR MEMBERSHIP NUMBER XXX
YEAR OF ADMISSION XXXX
U.S. STATE/ COMMONWEALTH/ TERRITORY XX
FIRM NAME AstraZeneca Pharmaceuticals LP
STREET 1800 Concord Pike, A2C
CITY Wilmington
STATE Delaware
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
ZIP/POSTAL CODE 19850-5437
PHONE 302-886-6926
FAX 302-885-3762
EMAIL ADDRESS Cara.Kearney@astrazeneca.com
DOMESTIC REPRESENTATIVE INFORMATION
NAME Cara M. Kearney
FIRM NAME AstraZeneca Pharmaceuticals LP
STREET 1800 Concord Pike, A2C
CITY Wilmington
STATE Delaware
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
ZIP CODE 19850-5437
PHONE 302-886-6926
FAX 302-885-3762
EMAIL ADDRESS Cara.Kearney@astrazeneca.com
CORRESPONDENCE INFORMATION
NAME Cara M. Kearney
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE Cara.Kearney@astrazeneca.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) trademarks@astrazeneca.com; lori.tittley@astrazeneca.com
FEE INFORMATION
APPLICATION FILING OPTION TEAS Standard
NUMBER OF CLASSES 1
APPLICATION FOR REGISTRATION PER CLASS 350
*TOTAL FEES DUE 350
*TOTAL FEES PAID 350
SIGNATURE INFORMATION
SIGNATURE /cmk/
SIGNATORY'S NAME Cara M. Kearney
SIGNATORY'S POSITION Attorney of record, Pennsylvania bar member
SIGNATORY'S PHONE NUMBER 3028866926
DATE SIGNED 06/22/2023
SIGNATURE METHOD Sent to third party for signature



PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


Trademark/Service Mark Application, Principal Register

Serial Number: 98054331
Filing Date: 06/22/2023

To the Commissioner for Trademarks:

MARK: WAINUA (Standard Characters, see mark)
The literal element of the mark consists of WAINUA. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, AstraZeneca AB, a corporation of Sweden, having an address of
      Astraallén
      Södertälje SE-15185
      Sweden
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 005:  Pharmaceutical preparations and substances for the treatment of amyloidosis
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

Priority based on foreign filing: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services and asserts a claim of priority based on European Union Trademark - EUTM application number 018888666, filed 06/15/2023.
INTENT TO PERFECT 44(d) : At this time, the applicant intends to rely on Section 44(e) as a basis for registration. If ultimately the applicant does not rely on Section 44(e) as a basis for registration, a valid claim of priority may be retained.




The owner's/holder's proposed attorney information: Cara M. Kearney. Cara M. Kearney of AstraZeneca Pharmaceuticals LP, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, is located at
      1800 Concord Pike, A2C
      Wilmington, Delaware 19850-5437
      United States
      302-886-6926(phone)
      302-885-3762(fax)
      Cara.Kearney@astrazeneca.com
The docket/reference number is 104563/US.
Cara M. Kearney submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant hereby appoints Cara M. Kearney of AstraZeneca Pharmaceuticals LP
      1800 Concord Pike, A2C
      Wilmington Delaware 19850-5437
      United States
      302-886-6926(phone)
      302-885-3762(fax)
      Cara.Kearney@astrazeneca.com
as applicant's representative upon whom notice or process in the proceedings affecting the mark may be served.

The applicant's current Correspondence Information:
      Cara M. Kearney
       PRIMARY EMAIL FOR CORRESPONDENCE: Cara.Kearney@astrazeneca.com
       SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): trademarks@astrazeneca.com; lori.tittley@astrazeneca.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $350 has been submitted with the application, representing payment for 1 class(es).

Declaration

Declaration Signature

Signature: /cmk/   Date: 06/22/2023
Signatory's Name: Cara M. Kearney
Signatory's Position: Attorney of record, Pennsylvania bar member
Signatory's Phone Number: 3028866926
Signature method: Sent to third party for signature
Payment Sale Number: 98054331
Payment Accounting Date: 06/22/2023

Serial Number: 98054331
Internet Transmission Date: Thu Jun 22 11:18:00 ET 2023
TEAS Stamp: USPTO/BAS-XXX.XX.XXX.XX-2023062211180109
4301-98054331-860e7545d2fe6d8bca2c9abb88
27ab8ac7110ffa6fe6e122b817501dcc2bf-DA-1
8005506-20230621151407605533

Application [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed